Trial Profile

Randomized trial of high-dose epirubicin and cyclophosphamide X 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide X 4 followed by cyclophosphamide, methotrexate and 5-fluorouracil X 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than or equal to 65 yrs) patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Mesna; Methotrexate; Tamoxifen
Indications Breast cancer; Early breast cancer
Focus Therapeutic Use

04 Apr 2013 Biomarkers information updated
20 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
20 Jul 2012 Additional trial location (USA) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com